VANDEROSTYNE

VANDEROSTYNE has been active since 1994 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €368,199 and a net result of €41,509. Equity is growing by ~7.7% per year across the filed fiscal years. Its solvency ranks better than 54% of 6032 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).